Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study.
Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study.
Clin Cancer Res. 2019 Aug 01;25(15):4859
Authors: Toulmonde M, Blay JY, Bouche O, Mir O, Penel N, Isambert N, Duffaud F, Bompas E, Esnaud T, Boidot R, Geneste D, Ghiringhelli F, Lucchesi C, Bellera CA, Le Loarer F, Italiano A
PMID: 31371309 [PubMed - in process]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Toulmonde M, Blay JY, Bouche O, Mir O, Penel N, Isambert N, Duffaud F, Bompas E, Esnaud T, Boidot R, Geneste D, Ghiringhelli F, Lucchesi C, Bellera CA, Le Loarer F, Italiano A Tags: Clin Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Gastroenterology | Gastrointestinal Stromal Tumor (GIST) | Gleevec | Study